Señales en vivo de MBRX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses...

Stats
Volumen de hoy	16 435.00
Volumen promedio	107 577
Capitalización de mercado	11.18M
EPS	$0 ( 2024-03-27 )
Próxima fecha de ganancias	( $-3.59 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.330
ATR14	$0.0790 (1.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Foster Jonathan P.	Buy	28 986	Common Stock
2023-12-26	George Robert E.	Buy	14 493	Common Stock
2023-12-26	Klemp Walter V	Buy	188 404	Common Stock
2023-07-11	Klemp Walter V	Sell	13 204	Restricted Stock Units
2023-07-11	Klemp Walter V	Buy	13 204	Common Stock

INSIDER POWER
82.97
Last 98 transactions
Buy: 6 351 373 \| Sell: 471 392

Moleculin Biotech Inc Correlación

10 Correlaciones Más Positivas
TXG	0.897
NEOG	0.894
BIRD	0.89
NDRA	0.886
ADPT	0.879
RVNC	0.878
GIII	0.874
GOCO	0.868
DCFC	0.865
NDLS	0.859

10 Correlaciones Más Negativas
QQD	-0.87
QQC	-0.867
PRTC	-0.857
BCOR	-0.834
RAIN	-0.823
MSSA	-0.82
HZNP	-0.819
LCYAU	-0.819
MSAC	-0.817
GHRS	-0.817

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Moleculin Biotech Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-222 000 (0.00 %)
EPS:	$-14.37

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$-164 000 (0.00 %)
EPS:	$-1.614

Financial Reports:

No articles found.

Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Actualizaciones en tiempo real para Moleculin Biotech Inc [MBRX]

Upcoming Earnings Alert